NIBRT collaborates with Valitacell to innovate the way that life-saving medicines are made.

 
Watch Valitacell expert Dr Karen Coss explain the current challenges that exist with cell culture media in biomanufacturing. Find out how our ChemStress technology tools for optimised cell culture media control.
 
 

The Enterpise Ireland co-funded initiative will help innovate the production of new biopharma therapies for patients.

[Dublin, 01/11/18]

Valitacell is partnering with the National Institute of Bioprocessing Research and training (NIBRT) to validate Valitacell’s novel analytical technology known as ChemStress™ which can accelerate the development and manufacture of live-saving biopharmaceutical drugs.

Screenshot 2018-11-01 at 11.15.41.png

Biologic drugs are precision medicines which are manufactured using living cells. These cells require feeding to grow and to produce the desired drug and this nutrition is provided by cell culture media which is a complex mix of amino acids, salts, glucose vitamins, and other nutrients.

Biopharmaceuticals have revolutionised the treatment of chronic diseases such as cancer and inflammatory disorders with 350 million patients benefitting from biological medicines worldwide. The collaboration, which also involves a number of large global biopharmaceutical companies, will demonstrate how Valitacell’s novel analytical platform - ChemStress™can be used as a quality control in cell culture media analysis. NIBRT’s Prof. Johnathan Bones will lead the project, along with Valitacell’s product manager Dr. Karen Coss.

Valitacell ChemStress technology enables companies to ensure that the media that they are adding to the cells meets the quality standards that they have set for themselves, through smart analytics.

Valitacell, founded in 2015, is a biotechnology company headquartered in Dublin. It was the recipient of the 2016 InterTrade All Ireland Seedcorn Award and in 2017 received €2.03 million in funding through the H2020 SME Programme for European Innovation.

Dr. Terry McWade, Valitacell CEO said: “We are delighted to be working with Prof Jonathan Bones and his team. Having access to outstanding researchers and facilities at NIBRT will enable us to accelerate the development of our technology and help in our goal or bringing life saving medicines to patients more quickly and at lower cost.”

Prof. Jonathan Bones, Principal Investigator, NIBRT Characterisation and Comparability Laboratory said: “NIBRT are delighted to engage with Valitacell on this exciting project. Valitacell are developing innovative technologies for monitoring the quality and behaviour of complex biomanufacturing processes. Our analytical platforms strongly complement Valitacell’s ChemStress™ technology and we share a common vision to ensure more efficient manufacturing of these key biological medicines.”

The biopharmaceutical industry is of critical importance to Europe’s economy, and there are tremendous opportunities to improve human health as well as contribute to economic growth and sustainability in the years to come. The project is an Innovation Partnership co-funded by Enterprise Ireland, the European Regional Development Fund (ERDF) and the EU. The €206,283 award will run over 18 months and the project will begin in November 2018.